Novo Nordisk inventory fell over 10% Monday after it stated its next-generation weight reduction drug did not meet its main goal.
The drug, CagriSema, did not obtain its main endpoint of demonstrating non-inferiority on weight reduction when in comparison with Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo stated in an announcement Monday morning.
Eli Lilly‘s inventory rose 2.1% in premarket buying and selling.
Novo is exploring further trials to check CagriSema, together with higher-dose mixtures, it stated.
That is breaking information. Please refresh for updates.
